-
很多恶性肿瘤发展到晚期都会出现骨转移[1-2],肿瘤骨转移往往会引起骨骼相关事件(skeletal-related events, SREs),进而严重影响患者的生活质量。SREs包括:①疼痛(50%~90%);②病理性骨折(5%~40%);③高钙血症(10%~20%);④脊柱不稳和脊髓、神经根压迫症状(<10%);⑤骨髓抑制(<10%)。乳腺癌、前列腺癌以及非小细胞肺癌常以骨转移为首显症状,到了晚期其骨转移发生率分别是80%、70%以上、24%~40%[3-5]。肿瘤骨转移目前尚无标准的规范化治疗方案,往往需要结合多种治疗方法进行综合治疗。双膦酸盐类药物和放射性药物是治疗多发骨转移的常用药物,对于两者的应用,目前较为普遍的还是单药治疗。对于两者联合用药的顾虑主要是担心两者会对彼此的疗效产生不利影响。尤其是担心双膦酸盐类药物会影响放射性药物的吸收[6-8]。
放射性药物联合双膦酸盐类药物治疗肿瘤骨转移研究现状
Concurrent use of radionuclides and bisphosphonates in bone metastasis: a review
-
摘要: 骨转移是恶性肿瘤远处转移最常见类型之一,其发生率仅次于肺转移和肝转移。前列腺癌、乳腺癌以及肺癌是骨转移发生率最高的恶性肿瘤,近70%的乳腺癌或前列腺癌发展到晚期都会发生骨转移。肿瘤骨转移往往会引起疼痛、骨折以及高钙血症等不适,从而严重影响患者的生活质量。肿瘤骨转移目前尚无标准的规范化治疗方案,往往需要结合多种治疗方法进行综合治疗。双膦酸盐类药物和放射性药物是目前临床治疗多发骨转移广泛应用的药物,对于两者的应用,目前较为普遍的还是单药治疗,关于两者是否应该联合应用的问题一直存在争议。笔者系统回顾了近年来关于放射性药物联合双膦酸盐类药物治疗的相关研究。Abstract: Bone is one of the most common sites of distant metastasis of malignant tumors, whose is second only to those of lung metastasis and liver metastasis. Malignant tumors with high incidence of bone metastasis include prostate cancer, breast cancer, and lung cancer, and nearly 70% of patients with advanced breast or prostate cancers have bone metastasis. Bone metastasis often causes pain, fracture, and hypercalcemia, which can seriously affect the quality of life. No standard treatment exists for tumor bone metastasis, and combining multiple therapies is often necessary. Bisphosphonates and radionuclides are extensively used individually to treat multiple bone metastases, but the concurrent use of both drugs is rarely researched. In this paper, recent studies on the concurrent use of radionuclides and bisphosphonates were reviewed.
-
Key words:
- Neoplasm metastasis /
- Radiopharmaceuticals /
- Combined modality therapy /
- Bisphosphonates
-
[1] Keller ET, Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity[J]. J Cell Biochem, 2004, 91(4): 718−729. DOI: 10.1002/jcb.10662. [2] Reddi AH, Roodman D, Freeman C, et al. Mechanisms of tumor metastasis to the bone: challenges and opportunities[J]. J Bone Miner Res, 2003, 18(2): 190−194. DOI: 10.1359/jbmr.2003.18.2.190. [3] Wang YP, Tao H, Yu XY, et al. Clinical significance of zoledronic acid and strontium-89 in patients with asymptomatic bone metastases from non-small-cell lung cancer[J]. Clin Lung Cancer, 2013, 14(3): 254−260. DOI: 10.1016/j.cllc.2012.09.001. [4] Yamada K, Yoshimura M, Kaise H, et al. Concurrent use of Sr-89 chloride with zoledronic acid is safe and effective for breast cancer patients with painful bone metastases[J]. Exp Ther Med, 2012, 3(2): 226−230. DOI: 10.3892/etm.2011.405. [5] 赵卫威, 解朋. 89Sr治疗前列腺癌骨转移的研究进展[J]. 中华男科学杂志, 2010, 16(3): 269−272. DOI: 10.13263/j.cnki.nja.2010.03.026.
Zhao WW, Xie P. Strontium-89 for bone metastases from prostate cancer: an update[J]. Nat J Androl, 2010, 16(3): 269−272. DOI: 10.13263/j.cnki.nja.2010.03.026.[6] Auclerc G, Antoine EC, Cajfinger F, et al. Management of advanced prostate cancer[J]. Oncologist, 2000, 5(1): 36−44. DOI: 10.1634/theoncologist.5−1−36. [7] Lewington VJ. Bone-seeking radionuclides for therapy[J]. J Nucl Med, 2005, 46(Suppl 1): S38−47. [8] Marcus CS, Saeed S, Mlikotic A, et al. Lack of effect of a bisphosphonate (pamidronate disodium) infusion on subsequent skeletal uptake of Sm-153 EDTMP[J]. Clin Nucl Med, 2002, 27(6): 427−430. DOI: 10.1097/00003072−200206000−00008. [9] Russell RGG. Bisphosphonates: the first 40 years[J]. Bone, 2011, 49(1): 2−19. DOI: 10.1016/j.bone.2011.04.022. [10] van Beek ER, Cohen LH, Leroy IM, et al. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates[J]. Bone, 2003, 33(5): 805−811. DOI: 10.1016/j.bone.2003.07.007. [11] Coleman RE. Bisphosphonates in breast cancer[J]. Ann Oncol, 2005, 16(5): 687−695. DOI: 10.1093/annonc/mdi162. [12] Clézardin P, Ebetino FH, Fournier PGJ. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity[J]. Cancer Res, 2005, 65(12): 4971−4974. DOI: 10.1158/0008−5472.CAN−05−0264. [13] Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel[J]. Ann Oncol, 2008, 19(3): 420−432. DOI: 10.1093/annonc/mdm442. [14] Saad F, Sternberg CN. Multidisciplinary management of bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy[J]. Nat Clin Pract Urol, 2007, 4(Suppl 1): S3−13. DOI: 10.1038/ncpuro0727. [15] James N, Pirrie S, Pope A, et al. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer[J]. Health Technol Assess, 2016, 20(53): 1−288. DOI: 10.3310/hta20530. [16] Powles T, Paterson S, Kanis JA, et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer[J]. J Clin Oncol, 2002, 20(15): 3219−3224. DOI: 10.1200/JCO.2002.11.080. [17] Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer[J]. J Natl Cancer Inst, 2004, 96(11): 879−882. DOI: 10.1093/jnci/djh141. [18] Storto G, Klain M, Paone G, et al. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases[J]. Bone, 2006, 39(1): 35−41. DOI: 10.1016/j.bone.2005.12.004. [19] Lam MGEH, de Klerk JMH, van Rijk PP, et al. Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases[J]. Anticancer Agents Med Chem, 2007, 7(4): 381−397. DOI: 10.2174/187152007781058596. [20] Choi JY. Treatment of bone metastasis with bone-targeting radiopharmaceuticals[J]. Nucl Med Mol Imaging, 2018, 52(3): 200−207. DOI: 10.1007/s13139−017−0509−2. [21] Harrison MR, Wong TZ, Armstrong AJ, et al. Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease[J/OL]. Cancer Manag Res, 2013, 5: 1-14[2018-04-26]. https://www.ncbi.nlm.nih.gov/pubmed/23326203. DOI: 10.2147/CMAR.S25537. [22] Parker CC, Coleman RE, Sartor O, et al. Three-year safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases from phase 3 randomized alpharadin in symptomatic prostate cancer trial[J]. Eur Urol, 2018, 73(3): 427−435. DOI: 10.1016/j.eururo.2017.06.021. [23] Saad F, Carles J, Gillessen S, et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial[J]. Lancet Oncol, 2016, 17(9): 1306−1316. DOI: 10.1016/S1470−2045(16)30173−5. [24] 郭佳, 宋文忠. 89Sr、双膦酸盐及二者联合治疗肿瘤多发性骨转移的系统评价[J]. 实用临床医药杂志, 2017, 21(11): 54−58.
Guo J, Song WZ. A systematic study of 89Sr, bisphosphonates and 89Sr plus bisphosphonates therapy for patients with bone metastases[J]. J Clin Med Pract, 2017, 21(11): 54−58.[25] 李宁, 柴华, 杨志, 等. 唑来膦酸联合89Sr治疗前列腺癌骨转移的临床疗效[J]. 国际放射医学核医学杂志, 2017, 41(4): 247−251. DOI: 10.3760/cma.j.issn.1673−4114.2017.04.003.
Li N, Chai H, Yang Z, et al. Clinical observation of zoledronic acid combined with 89Sr in the treatment of prostate cancer patients with bone metastases[J]. Int J Radiat Med Nucl Med, 2017, 41(4): 247−251. DOI: 10.3760/cma.j.issn.1673−4114.2017.04.003.[26] 白永利, 王林, 董莉. 唑来膦酸钠联合89SrCl2治疗骨转移瘤的临床疗效[J]. 现代肿瘤医学, 2016, 24(5): 815−818. DOI: 10.3969/j.issn.1672−4992.2016.05.039.
Bai YL, Wang L, Dong L. Clinical observation of zoledronic acid combined with 89SrCI2 in the treatment of bone metastasis tumor[J]. Med Oncol, 2016, 24(5): 815−818. DOI: 10.3969/j.issn.1672−4992.2016.05.039.[27] 李梅, 王火强. 89SrCl2联合伊班膦酸钠对肺癌骨转移骨痛的疗效分析[J]. 放射免疫学杂志, 2013, 26(4): 390−392. DOI: 10.3969/j.issn.1008−9810.2013.04.003.
Li M, Wang HQ. Therapeutic efficacy of 89SrCl2 combined with ibandronate in the treatment of osseous metastasis of lung cancer[J]. J Radioimmunol, 2013, 26(4): 390−392. DOI: 10.3969/j.issn.1008−9810.2013.04.003.[28] Lam MGEH, Dahmane A, Stevens WHM, et al. Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases[J]. Eur J Nucl Med Mol Imaging, 2008, 35(4): 756−765. DOI: 10.1007/s00259−007−0659−z. [29] Waldert M, Klatte T, Remzi M, et al. Is 153Samarium-ethylene-diamine-tetramethyl-phosphonate (EDTMP) bone uptake influenced by bisphosphonates in patients with castration-resistant prostate cancer?[J]. World J Urol, 2012, 30(2): 233−237. DOI: 10.1007/s00345−011−0685−0. [30] Lam MGEH, de Klerk JMH, Zonnenberg BA. Treatment of painful bone metastases in hormone-refractory prostate cancer with zoledronic acid and samarium-153-ethylenediaminetetramethylphosphonic acid combined[J]. J Palliat Med, 2009, 12(7): 649−651. DOI: 10.1089/jpm.2009.9591. [31] Suominen MI, Rissanen JP, Käkönen R, et al. Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis[J]. J Natl Cancer Inst, 2013, 105(12): 908−916. DOI: 10.1093/jnci/djt116. [32] Rasulova N, Lyubshin V, Arybzhanov D, et al. Optimal timing of bisphosphonate administration in combination with samarium-153 oxabifore in the treatment of painful metastatic bone disease[J]. World J Nucl Med, 2013, 12(1): 14−18. DOI: 10.4103/1450−1147.113939.
计量
- 文章访问数: 11191
- HTML全文浏览量: 10647
- PDF下载量: 24